Skip to main content
NCBI home page
Journal of Cardiovascular and Thoracic Research logoLink to Journal of Cardiovascular and Thoracic Research
. 2018 May 28;10(2):56–69. doi: 10.15171/jcvtr.2018.10

Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis

Jamal Hallajzadeh 1, Maliheh Khoramdad 2, Nahid Karamzad 3, Amir Almasi-Hashiani 4, Ali Janati 5, Erfan Ayubi 6, Reza Pakzad 7, Mark JM Sullman 8, Saeid Safiri 1,9,*
PMCID: PMC6088762  PMID: 30116503

Abstract

Introduction: The objectives of this study were to provide an estimate of the prevalence of metabolic syndrome (MetS ) and its components among women with PCOS; and calculate the odds ratio (OR) for MetS (using different definitions of MetS) in women with PCOS, compared to healthy controls.

Methods: All of the relevant databases were used to search for appropriate articles that were published during the period 2003-2016. We included observational studies (cross-sectional, comparative cross-sectional) among women who met the inclusion criteria. The random-effect models were used to pool the prevalence of MetS and its components among PCOS women. This model was also applied to the pooled OR assessing the association between MetS and PCOS.

Results: The pooled prevalence of MetS among PCOS women was found to be 26.30% (95% CI: 23.68–28.93), but varied from 7.10% (95% CI: 1.64-12.56) to 37.50% (95% CI: 28.84-46.16), depending upon the diagnostic criteria used. Low high-density lipoprotein cholesterol (HDL) - 61.87% (95% CI: 53.31–70.43) and high waist circumference (WC)- 52.23% (95% CI: 43.84–60.61) were the most common components of MetS in PCOS women. Compared to healthy controls, the overall pooled (OR) of MetS in PCOS patients was 2.09 (95% CI: 1.67-2.60), but this ranged from 0.31 (95% CI: 0.13-0.74) to 4.69 (95% CI: 2.09-10.52), depending upon the diagnostic criteria used.

Conclusion: Women with PCOS had a much higher prevalence of MetS than was found among the healthy controls. Furthermore, as low HDL and high WC were the most common components of MetS in PCOS women, these two components specifically need to be addressed in prevention strategies.

Keywords: Global, Metabolic Syndrome, Prevalence, Polycystic Ovary Syndrome, Meta-Analysis

Introduction

Polycystic ovary syndrome (PCOS) is one of the most important clinical and public health problems facing women, and has been reported to affect more than 20% of reproductive aged women.1 It has been estimated that the total cost of evaluating and providing care for reproductive-aged PCOS women in the United States is around $4.36 billion, excluding any potential obstetric complications.2 This syndrome has been found to be associated with significant adverse sequelae that can degrade long-term health and well-being. The short-term morbidities of PCOS include dermatologic, reproductive, and mood disturbances, while the longer-term morbidities of PCOS include vascular dysfunction, neoplastic, and mental health disorders.3 In addition, women with PCOS tend to have other abnormalities, such as: hypertension, dyslipidemia, insulin resistance, impaired glucose tolerance, obesity, and diabetes mellitus. Consequently, women with PCOS are highly susceptible to metabolic syndrome (MetS).4,5 MetS has recently been estimated to have a prevalence of about 23.8%-53.3% among women suffering from PCOS.6-8 A similar range in the prevalence of MetS components has also been reported.8-10 The variation in research findings may be due to differences among the participants included in each study, such as: diet, lifestyle and genetic factors. However, one obvious reason for the wide range in the prevalence of MetS is the definition used to diagnose MetS.11 There are a number of definitions of MetS, which mainly differ according to the number of components required and the cut-off points used (Table 1).

Table 1. Summary of the MetS definitions .

Definitions WHO NCEP-ATP III IDF EGIR AACE AHA/NHLBI ATP III JS 2009
Number of Criteria Two or more of: Three or more of: Two or more of : Two or more of: Obesity and two or more of: Three or more of: Three or more of: Three or more of:
Obesity BMI > 30 and/or WHR > 0.9 (men), WHR > 0.85 (women) WC ≥ 102 cm (men), WC ≥ 88 cm (women WC ≥ 94 cm men, WC ≥ 80 cm women WC ≥ 94 cm
(men, WC ≥80 cm (women) 		WC ≥ 102 cm (men), WC ≥ 88 cm (women BMI ≥ 30 kg/m2 WC ≥ 102 cm (men), WC ≥ 88 cm (women Population- and country-specific definitions
Blood pressure mm Hg ≥ 140/90 ≥ 130/85 or treatment ≥130/≥85 or treatment ≥ 140/90 ≥ 130/85 or treatment ≥130/85 mm Hg or previous hypertension diagnosis ≥ 130/85 or treatment ≥ 130/85 or treatment
Dyslipidmia
HDL-C ≥ 35 mg/dL (0.9 mmol/L) in men or ≥ 39 mg/dL (≥ 1.0 mmol/L) in women ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment ≥ 39 mg/dL (1.0 mmol/L) or treatment ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women ≥ 40 mg/dL (1.03 mol/L) in men, ≥ 50 mg/dL (1.29 mmol/L) in women, or treatment
Triglycerides ≥178 mg/dL(2.0 mmol/L) or treatment ≥150 mg/dL (1.7 mmol/L) or treatment ≥150 mg/dL (1.7 mmol/L) or treatment ≥150 mg/dL (1.7 mmol/L) ≥150 mg/dL (1.7 mmol/L) or treatment ≥150 mg/dL (1.7 mmol/L) or treatment ≥150 mg/dL (1.7 mmol/L) ≥150 mg/dL (1.7 mmol/L) or treatment
Glucose Intolerance or Fasting Plasma Glucose ≥110 mg/dL (6.1 mmol/l), DM, IGT, IR ≥100 mg/dL (5.6 mmol/L) or T2D ≥100 mg/dL (5.6 mmol/L) or T2D ≥110 mg/dL (6.1 mmol/L) ≥110 mg/dL (6.1 mmol/l), or treatment ≥100 mg/dL (5.6 mmol/L) or T2D ≥110 mg/dL (6.1 mmol/L) ≥100 mg/dL (5.6 mmol/L) or T2D
Open in a new tab

BMI = body mass index; JC= Joint Consensus; DM = diabetes mellitus; EGIR = European Group against Insulin Resistance; HDL-C = high-density lipoprotein cholesterol; IDF = International Diabetes Federation; IGT = impaired glucose tolerance; IR = insulin resistance; NCEP ATPIII = National Cholesterol Education Program Adult Treatment Panel; AACE= American Association of Clinical Endocrinologists; AHA/NHLBI= The American Heart Association / National Heart, Lung, and Blood Institute; JS= Joint Statement; T2 D, type II diabetes mellitus; WC = waist circumference; WHO = World Health Organization; WHR = waist hip ratio.

The relationship between PCOS and MetS has been studied a number of times, with several studies reporting MetS to be more prevalent among women with PCOS than among women of the same age without PCOS.11-13 In contrast, there are also studies which have reported a higher rate of MetS among healthy women, than among those diagnosed with PCOS.14

In fact, despite a number of studies being conducted in different parts of the world, there has not yet been a comprehensive study of the prevalence of MetS and its components among women diagnosed with PCOS15 Therefore, the objectives of this systematic review and meta-analysis were to: 1) update the prevalence of MetS in women with PCOS, based on commonly used definitions of MetS; 2) determine the prevalence of MetS components among this group of women; and 3) calculate the odds ratio for MetS (using different definitions of MetS) among women with PCOS, in comparison to healthy controls.

Methods

Search strategy and study selection

We conducted a systematic review and meta-analysis using the “Preferred Reporting Items for Systematic Reviews and Meta-Analysis” (PRISMA) guidelines.16 The review included all articles published from 2003 to 2016 which measured the prevalence of MetS and/or the components of this syndrome (i.e., waist circumference - WC, blood pressure - BP, high-density lipoprotein cholesterol -HDL-C, triglycerides - TG, fasting blood sugar - FBS) among women diagnosed with PCOS.

The keywords were initially extracted using the medical subject headings (MESH) in Medline, which were: “metabolic syndrome”, “dysmetabolic syndrome”, “cardiovascular syndrome”, “insulin resistance syndrome”, “polycystic ovary syndrome”, “PCOS”, “Prevalence”, “odds ratio”, “cross-sectional studies”, “comparative cross-sectional studies” and “case-control studies”. These keywords were then used to search the following databases: PubMed, Web of Science, Medline, Scopus, Embase, CABI, CINAHL, DOAJ, and Index Medicus for Eastern Mediterranean Region-IMEMR. In addition, Google Scholar was used to search the grey literature, as recommended by previous research,17 using the abovementioned search strategy. Finally, in an attempt to gather additional articles, an expert in the subject area was consulted.

Inclusion and exclusion criteria

Articles were included from observational studies (cross-sectional, and comparative cross-sectional) which met the following criteria: (a) diagnosis of PCOS using the Rotterdam criteria, which includes women with at least two of the three symptoms (i.e., polycystic ovaries, oligo-ovulation or anovulation and clinical and/or biochemical signs of hyperandrogenism); and (b) MetS, or its components, diagnosed in women with PCOS (or those without PCOS), based upon a standard definition. Original articles were included irrespective of age or race. However, studies were excluded where: (a) an unclear definition of MetS was provided; (b) the data reported were insufficient to determine the prevalence of MetS; and (c) patients were suffering from other clinical disorders. In cases where the data were not included in the published articles, we contacted one of the authors (first/corresponding authors) at least twice in an attempt to obtain the required information.

Data extraction and quality assessment

Two researchers (SS and JH), independently took responsibility for entering data in the review and a third researcher was consulted when any differences were identified. The variables extracted from the articles were: study characteristic (first author’s name, date of publication, and country of origin); participant characteristics (gender, age, and sample size); MetS prevalence, as well as the definition(s) used; and the prevalence of MetS components (WC, BP, HDL-C, TG, FBS). The quality of the study was also measured using the STROBE checklist (22 items). Those which met the minimum acceptable quality criteria (>15 items) were included in the analysis.18 It is important to mention that the risk was assessed using the Newcastle–Ottawa scale.19 The research design, recruitment strategy, response rate, representativeness of the sample, objectivity of the outcome, power calculation provided, and appropriate statistical analyses were also evaluated.19 The minimum and maximum scores were 0 and 9, respectively. The studies were then categorized as low risk (≥6), moderate risk (<6 but >3) and high risk (<3).

Statistical analysis

A random-effects model was used to analyze the prevalence of MetS, and its components, among women with PCOS. An odds ratio (OR) was used to illustrate the association between MetS and PCOS, also using a random effects model. Heterogeneity between studies was examined using the I2 index and a random-effects model was again used where heterogeneity was identified (I2> 0.6). Meta-regression was used to identify the source of heterogeneity and publication bias was investigated using a funnel plot and Egger’s test.20 All statistical tests were conducted using Review Manager (RevMan) version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and Stata software version 13 (Stata Corp, College Station, TX, USA).

Results

A total of 1458 records were identified through the combined search of the databases. However, following elimination of the non-eligible studies, a total of 72 cross-sectional studies and 35 comparative cross-sectional studies were retained to estimate the prevalence and risk of MetS among women with PCOS. Figure 1 depicts the flow chart used in the study selection. Articles were identified from 20 different countries during the period 2003-2015, with the majority of these originating from the United States. Surprisingly, there were no articles identified from Africa. The age range of individuals who had taken part in these studies ranged from 15-54 years old. The MetS definition used in this study was based on the NCEP-ATP III criteria. The characteristics of the studies included in this research are reported in Tables 2 and 3.

Figure 1.

Figure 1

Flow diagram of the study selection process.

Open in a new tab

Table 2. Prevalence of metabolic syndrome in women with and without PCOS .

First Author Country Criteria Study year Publication Year Characteristics of People with PCOS Characteristics of People without PCOS Reference
Age Range Mean Age Total Sample Prev. MetS Age Range Mean Age Total Sample Prev. MetS
Kyrkou G Greece IDF - 2015 - 24.7 230 12.6 - 24.1 155 1.9 21
Romanowski MD Brazil NCEP-ATP III 2008-2009 2015 - 26.8 101 32.7 - 33.7 77 19.5 22
Romanowski MD Brazil IDF 2008-2009 2015 - 26.8 101 44.6 - 33.7 77 28.6 22
Pillai BP India IDF 2010-2012 2015 12-41 24.8 121 52.0 - - - - 23
Pillai BP India NCEP-ATP III 2010-2012 2015 12-41 24.8 121 30.6 - - - - 23
Madani T Iran NCEP-ATP III 2015 - 28.6 624 19.7 - - - - 24
Shabir I India IDF 2009-2010 2014 13-28 23.0 37 27.0 - - - - 25
Shabir I India ATP III 2009-2010 2014 13-28 23.0 37 22.0 - - - - 25
Figurova J Slovakia NCEP-ATP III 2010-2013 2014 20-41 29.2 99 21.2 - - - - 26
Tehrani FR Iran IAMC 2010-2012 2014 18-45 29.1 85 7.1 - 33.9 517 19.53 27
Rong Li China NCEP-ATP III - 2014 19-45 29.1 833 19.1 - 32.3 2732 14.7 28
Kim MJ Korea NCEP-ATP III 2010-2011 2014 15-40 27.9 837 16.7 - - - - 29
Panidis D Greece NCEP-ATP III - 2013 - 24.7 1223 15.8 - 31.3 277 10.1 30
Panidis D Greece AHA-NHLBI - 2013 - 24.7 1223 23.9 - 31.3 277 18.8 30
Panidis D Greece IDF - 2013 - 24.7 1223 28.9 - 31.3 277 23.8 30
Panidis D Greece Joint Defintion - 2013 - 24.7 1223 29.5 - 31.3 277 23.8 30
Mandrelle K India Modified AHA ATP III 2009-2010 2012 19-38 26.1 120 37.5 - - - - 31
Moini A Iran NCEP-ATP III 2008-2009 2012 15-40 28.0 282 22.7 - - - - 32
Verit FF Turkey NCEP-ATP III 2004-2010 2012 18-34 26.0 163 25.7 - 26.3 53 26.3 33
Ishak A Malaysia IDF 2008-2010 2012 18-41 29.6 99 43.4 - - - - 34
Bhattacharya SM India JS 2009 2007-2008 2011 - 17.0 96 60.8 - 35
Mehrabian F Iran NCEP-ATP III 2006-2008 2011 18-42 - 539 24.9 - - - - 36
Hudecova M Sweden NCEP-ATP III - 2011 15-46 43.0 84 23.8 - 43.7 87 8.0 6
VrbÍková J Czech Republic IDF - 2011 22-28 16.8 43 11.6 22-27 17.5 48 2.1 37
Gangale MF Italy ATP III - 2011 22-31 140 18.6 - - - - 38
Hosseinpanah F Iran JS 2009-2010 2011 25-39 31.0 136 15.4 30-41 36.0 423 17.1 39
Dey R India NCEP-ATP III 2006–2007 2011 15-35 50 42.0 - - - - 40
Bhattacharya SM India IDF 2004-2006 2010 15-40 22.1 198 47.5 - - - - 41
Bhattacharya SM India ATP III 2004-2006 2010 - 22.2 198 37.9 - - - - 41
Indhavivadhana S Thailand NCEP-ATP III 2007 2010 - 25.4 250 18.0 - - - - 42
Indhavivadhana S Thailand IDF 2007 2010 - 25.4 250 21.2 - - - - 42
Indhavivadhana S Thailand AHA/NHLBI 2007 2010 - 25.4 250 21.2 - - - - 42
Fruzzetti F Italy Ferranti 2006-2007 2009 12-19 17.2 53 9.4 - - - - 43
Moradi S Iran ATP III - 2009 16-48 28.0 151 46.4 - - - - 44
Ni R China IDF 2004-2008 2009 20-41 27.0 578 16.8 - - - - 45
Gambineri A Italy NCEP-ATP III - 2009 14-49 26.1 200 32.0 14-49 26.8 200 23.0 46
Gambineri A Italy IDF - 2009 14-49 26.1 200 39.0 14-49 26.8 200 25.0 46
Gambineri A Italy AHA/NHLBI - 2009 14-49 26.1 200 37.0 14-49 26.8 200 24.0 46
Soares EMM Brazil NCEP-ATP III 2004-2005 2008 20-34 26.4 102 28.4 - - - - 47
Attaoua R Romania NCEP-ATP III - 2008 19-57 23.1 107 15.8 - 34.1 100 4.0 48
Cheung LP China ATP III (Modified) 2003-7 2008 - 30.2 295 24.9 - - - - 49
Cussons AJ Australia WHO 2000-5 2008 25-54 34.3 168 33.3 25-53 33.7 883 - 50
Cussons AJ Australia NCEP-ATP III 2000-5 2008 25-54 34.3 168 36.9 25-53 33.7 883 10.0 50
Cussons AJ Australia IDF 2000-5 2008 25-54 34.3 168 39.9 25-53 33.7 883 13.5 50
Gulcelik NE Turkey NCEP-ATP III - 2008 - 24.6 30 33.3 - 26.1 60 11.7 51
Costa L Brazil NCEP-ATP III 2005-6 2007 19-38 24.1 90 30.4 19-38 30.9 44 6.8 52
Costa L Brazil IDF 2005-6 2007 19-38 24.1 90 32.6 19-38 30.9 44 9.1 52
Weerakiet S Thailand IDF 2002-5 2007 - 28.8 170 35.3 - - - - 53
Marcondes JAM Brazil NCEP-ATP III 1995-2004 2007 - 25.0 73 38.4 - - - - 54
Caliskan E Turkey NCEP-ATP III 2004-6 2007 - 23.2 182 8.2 - 23.6 182 2.7 55
Caliskan E Turkey IDF 2004-6 2007 - 23.2 182 14.3 - 23.6 182 2.7 55
Caliskan E Turkey WHO 2004-6 2007 - 23.2 182 8.2 - 23.6 182 2.7 55
Caliskan E Turkey AHA/NHLBI 2004-6 2007 - 23.2 182 10.4 - 23.6 182 6.6 55
Shroff R USA AHA - 2007 - 32.0 24 25.0 - 24.0 36 17.0 56
Park HR Korea NCEP-ATP III - 2007 16-39 26.0 113 14.5 30-80 46.9 774 4.3 7
Hahn S Germany NCEP-ATP III - 2006 - 28.0 411 33.8 - 28.0 82 7.3 57
Carmina E USA ATP III 1991-2004 2006 18-40 24.9 282 8.2 - 25.2 85 2.4 11
Carmina E USA WHO 1991-2004 2006 18-40 24.9 282 16.0 - 25.2 85 2.4 11
Ehrmann DA USA ATP III - 2006 18-41 28.4 368 33.4 - - - - 10
Alvarez-Blasco F Spain ATP III 2002-5 2006 - 26.0 32 25.0 - 32.0 72 26.0 58
Coviello AD USA Cook - 2006 14-19 17.0 49 37.0 - - - - 59
Coviello AD USA Ferranti - 2006 14-19 17.0 49 47.0 - - - - 59
Leibel NL USA C-III - 2006 12-19 16.0 36 19.4 - - - - 60
Leibel NL USA C-04 - 2006 12-19 16.0 36 27.8 - - - - 60
Apridonidze T USA NCEP-ATP III 2000-3 2005 20-40 29.9 106 43.0 - - - - 12
Dokras A USA ATP III 2002 2005 18-49 28.0 129 47.3 18-50 44.0 177 6.8 4
Rabelo-Acevedo M Puerto Rico ATP III - 2005 19-57 29.4 39 44.0 - - - - 61
Vrbikova J Czech Republic ATP III 2001-3 2005 22-28 24.0 69 1.6 22-27 23.8 73 0 37
Vural B Turkey NCEP-ATP III 2002-4 2005 18-22 21.4 43 2.3 18-22 20.8 43 0 62
Vural B Turkey WHO 2002-4 2005 18-22 21.4 43 11.6 18-22 20.8 43 0 62
Faloia E Italy NCEP-ATP III - 2004 - 22.0 50 8.0 - - - - 63
Glueck CJ USA ATP III - 2003 - 31.0 138 46.4 - - 1887 22.8 64
Open in a new tab

Table 3. Prevalence of Metabolic Syndrome Components in Women with PCOS .

First Author Country Criteria Study year Publication Year Characteristics of people with PCOS Ref.
Age range Mean age Total sample Pr. WC (%) Pr. HTN (%) Pr. HDL (%) Pr. FBS (%) Pr. TG (%)
Kyrkou G Greece IDF - 2015 14–44 24.7 230 72.2 12.6 26.1 7.0 10.4 21
Madani T Iran NCEP-ATP III 2012-2013 2015 - 28.6 624 34.6 2.2 71.5 13.1 26.0 24
Shabir I India IDF 2009-2010 2014 13-28 23.0 37 67.5 22.0 NE 36.0 48.0 25
Shabir I India ATP III 2009-2010 2014 13-28 23.0 37 67.5 22.0 NE 36.0 48.0 25
Rong Li China NCEP-ATP III - 2014 19-45 29.1 833 84.8 45.7 85.9 55.0 63.4 28
Mandrelle K India Modified AHA ATP III 2009-2010 2012 19-38 26.1 120 45.8 20.0 91.7 8.3 - 31
Moini A Iran NCEP-ATP III 2008-2009 2012 15-40 28.0 282 31.0 10.6 68.8 3.2 33.0 32
Verit FF Turkey NCEP-ATP III 2004-2010 2012 18-34 26.0 163 26.4 17.8 42.3 12.3 22.1 33
Hudecova M Sweden NCEP-ATP III - 2011 15-46 43.0 84 46.4 NE NE 8.3 21.4 6
Hosseinpanah F Iran JIS 2009-2010 2011 18-45 31.0 136 81.0 NE 95.2 NE 87.7 39
Bhattacharya SM India IDF 2004-2006 2010 - 22.1 198 NE 68.1 98.9 68.1 98.9 35
Bhattacharya SM India ATP III 2004-2006 2010 - 22.2 198 NE 52.0 98.7 52.0 98.7 35
Indhavivadhana S Thailand NCEP-ATP III 2007 2010 - 25.4 250 48.8 14.0 39.6 6.8 17.2 42
Indhavivadhana S Thailand IDF 2007 2010 - 25.4 250 48.8 14.0 39.6 6.8 17.2 42
Indhavivadhana S Thailand AHA/NHLBI 2007 2010 - 25.4 250 48.8 14.0 39.6 6.8 17.2 42
Fruzzetti F Italy Ferranti 2006-2007 2009 12-19 17.2 53 28.3 28.3 43.4 1.9 7.5 43
Moradi S Iran ATP III - 2009 16-48 28.0 151 55.6 23.0 71.0 7.3 48.0 44
Ni R China IDF 2004-2008 2009 20-41 27.0 578 38.4 16.1 41.6 19.8 41.6 45
Gambineri A Italy NCEP-ATP III - 2009 14-49 26.1 200 57.0 50.0 58.0 6.0 11.0 46
Gambineri A Italy IDF - 2009 14-49 26.1 200 57.0 50.0 58.0 17.0 11.0 46
Gambineri A Italy AHA/NHLBI - 2009 14-49 26.1 200 57.0 50.0 58.0 17.0 11.0 46
Soares EMM Brazil NCEP-ATP III 2004-2005 2008 20-34 26.4 102 57.9 18.6 69.6 2.9 31.7 47
Cheung LP China ATP III (Modified) 2003-7 2008 - 30.2 295 53.1 29.4 28.6 21.4 21.4 49
Gulcelik NE Turkey NCEP-ATP III - 2008 - 24.6 30 21.0 6.0 48.0 2.0 17.0 51
Costa L Brazil NCEP-ATP III 2005-6 2007 19-38 24.1 90 47.8 28.2 52.2 4.3 8.7 52
Costa L Brazil IDF 2005-6 2007 19-38 24.1 90 47.8 28.2 52.2 4.3 8.7 52
Weerakiet S Thailand IDF 2002-5 2007 - 28.8 170 55.9 28.2 59.4 23.5 25.9 53
Marcondes JAM Brazil NCEP-ATP III 1995-2004 2007 - 25.0 73 49.3 24.7 67.6 6.9 31.8 54
Caliskan E Turkey NCEP-ATP III 2004-6 2007 - 23.2 182 19.2 15.4 61.0 5.5 5.5 55
Caliskan E Turkey IDF 2004-6 2007 - 23.2 182 19.2 15.4 61.0 5.5 5.5 55
Caliskan E Turkey WHO 2004-6 2007 - 23.2 182 19.2 15.4 61.0 5.5 5.5 55
Caliskan E Turkey AHA/NHLBI 2004-6 2007 - 23.2 182 19.2 15.4 61.0 5.5 5.5 55
Park HR Korea NCEP-ATP III - 2007 16-39 26.0 113 24.0 20.2 45.1 0.9 13.3 7
Hahn S Germany NCEP-ATP III - 2006 - 28.0 411 74.4 45.5 44.8 15.1 23.4 57
Carmina E USA ATP III 1991-2004 2006 18-40 24.9 282 39.0 7.3 45.1 3.1 9.3 11
Carmina E USA WHO 1991-2004 2006 18-40 24.9 282 39.0 7.3 45.1 3.1 9.3 11
Ehrmann DA USA ATP III - 2006 18-41 28.4 368 80.0 21.0 66.0 5.0 32.0 10
Alvarez-Blasco F Spain ATP III 2002-5 2006 - 26.0 32 66.0 25.0 72.0 6.0 19.0 58
Coviello AD USA Cook - 2006 14-19 17.0 49 47.0 41.0 84.0 2.0 49.0 59
Coviello AD USA Ferranti - 2006 14-19 17.0 49 65.0 41.0 84.0 2.0 53.0 59
Apridonidze T USA NCEP-ATP III 2000-3 2005 20-39 29.9 106 67.0 45.0 68.0 3.8 35.0 12
Rabelo-Acevedo M Puerto Rico ATP III - 2005 19-57 29.4 39 89.5 36.0 71.0 - 43.0 61
Vrbikova J Czech Republic ATP III 2001-3 2005 22-28 24.0 64 11.0 13.0 34.8 0.0 5.8 37
Glueck CJ USA ATP III - 2003 - 31.0 138 85.5 44.9 64.5 5.1 32.6 64
Open in a new tab

Prevalence of MetS and its component in women with PCOS

The pooled prevalence of MetS among PCOS women was found to be 26.30% (95% CI: 23.68–28.93). However, the pooled prevalence differed according to the definition of MetS used and were as follows: NCEP-ATP III (23.52%, 95% CI:20.21-26.83); IDF (30.81, 95% CI: 24.69–36.93); ATP III (29.36, 95% CI: 19.36–39.36); IMAC (7.10 , 95% CI: 1.64–12.56); JS (34.67, 95% CI: 16.77–52.58); Modified AHA-ATPIII (37.50, 95% CI: 28.84–46.16); AHA-NHLBI (23.12, 95% CI: 14.98–31.26); Ferranti (27.74%, 95% CI: 9.10–64.57); WHO (17.16, 95% CI: 7.28–27.05); Cook (37.00, 95% CI: 23.48–50.52); C-III (19.40, 95% CI: 6.48–32.32); and C-04 (27.80, 95% CI: 13.17–42.43) (Figure 2).

Figure 2.

Figure 2

Forest plot of MetS prevalence among women with PCOS by definition/criteria.

Open in a new tab

The pooled prevalence of MetS components in women diagnosed with PCOS are presented in online Figure S1-S5 (See Supplementary file 1). The prevalence of the individual components of MetS in women diagnosed with PCOS were: high FBS - 13.44% (95% CI: 9.05–17.84), low HDL - 61.87% (95% CI: 53.31–70.43), HTN - 26.69% (95% CI: 20.34–33.3), high TG - 33.09% (95% CI: 18.82–47.35) and high WC - 52.23% (95% CI: 43.84–60.61).

Association between PCOS and MetS

This meta-analysis also estimated the odds of MetS in woman diagnosed with PCOS and compared the prevalence of MetS with healthy women (i.e., not diagnosed with PCOS) using comparative cross-sectional studies. Additionally, the association between PCOS and MetS was examined using OR. In general, the odds of being diagnosed with MetS increased two fold for those diagnosed with PCOS (OR=2.09, 95% CI: 1.67–2.60), in comparison with the healthy controls. This OR varied widely, according to the MetS definition used, and included the following: NCEP-ATP III - 2.60 (95% CI: 1.77–3.84); IDF - 2.28 (95% CI: 1.33–3.89); IAMC - 0.31(95% CI: 0.13–0.74); AHA-NHLBI - 1.54 (95% CI: 1.21–1.96); JS - 1.16 (95% CI: 0.79–1.70); WHO - 4.69 (95% CI: 2.09–10.52); and ATP III - 2.23 (95% CI: 1.14–4.38) (Figure 3).

Figure 3.

Figure 3

Forest plot of MetS risk among patients with PCOS compared with healthy controls, by definition/criteria.

Open in a new tab

Heterogeneity and Meta-regression

Due to the significant heterogeneity in the ORs reported by the different studies (χ2=1251.39 df=71 P<0.00001 and I2=94%), a number of variables were entered into a meta-regression model in order to identify the source (s) of the heterogeneity. Criteria, publication date, continent and age were examined in this model, but only criteria and Publication date were statistically significant (P<0.001) (Table 4).

Table 4. Association between studied covariates with the MetS odds ratio among PCOS patients, compared to healthy controls .

Variables Meta-regression
Univariate Multivariate a
P value P value
Criteria 0.004 0.001
Publication date <0.001 <0.001
Continent 0.95
Mean age 0.68 -
Open in a new tab

aBetween-study variance assessed by moment-based estimate (tau2= 0.22).

Therefore, a subgroup analysis was conducted using publication date and diagnostic criteria used. The subgroup analysis also confirmed the results of the meta-regression, in that the OR for the relationship between PCOS and MetS was found to be different according to the research period, with studies conducted during 2003-2010 having a higher OR (OR = 3.02; 95% CI: 2.32-3.93) than those conducted from 2011-2015 (OR = 1.27; 95% CI: 1.03-1.58). Interestingly, the more recent studies reported a weaker association between PCOS and MetS than the earlier studies.

Publication bias

The publication bias in relation to the OR for MetS among women diagnosed with PCOS (compared to the healthy controls) was examined using funnel plots and Egger’s test. Figure 4 shows that there was no significant publication bias (P=0.112). Notably, the risk of bias assessment showed that the majority of the studies included had acceptable validity and no study was found to have a score lower than 3 (Table S1, online Supplementary file 1).

Figure 4.

Figure 4

Funnel plot assessing the publication bias on the association between MetS and PCOS.

Open in a new tab

Discussion

This study found that the general prevalence of MetS in women with PCOS varied according to the definition used. The highest prevalence of 37.50% was identified using the modified AHA ATP III definition, while the lowest prevalence was 7.10%, using the IAMC definition. Similar differences have also been observed in other studies.30,55

Using a cross-sectional study, the prevalence of MetS in patients with PCOS, based on the WHO criteria, was found to be 33%. However, using the NCEP-ATP-III and IDF criteria, these estimates were found to be 37% and 40%, respectively.50 These findings support previous research, which also found the IDF criteria to be more sensitive than the NCEP-ATP III criteria in identifying PCOS subjects with MetS (52% vs. 30.6%).23 The present findings also supported research by Bhattacharya, which found the prevalence of MetS among women with PCOS to be 37.9% and 47.5% using the NCEP-ATP III and IDF criteria, respectively.65 In another study, which used four definitions of MetS (NCEP-WHO-AHA/NCLBI-IDF), the IDF definition was again found to be the most sensitive in identifying MetS cases. This might be the result of the lower values of both waist circumference and FBS levels used in the IDF criteria.55

The present study found a significant relationship between PCOS and MetS (OR=2.09), which ranged from 0.31 to 4.69, depending upon the definition of MetS used. This association has been examined previously by a number of studies.30,50,55 For instance, research using the NCEP-ATP III definition reported a higher prevalence of MetS in women suffering from PCOS than among healthy controls.30 The same study also reported that there was no significant relationship between PCOS and MetS when using the AHA/NHLBI, IDF and Joint definitions.30 Moreover, Çalışkan et al. showed a greater prevalence of MetS among patient with PCOS, than in the control group, when using all criteria except for AHA/NCLBI.55 In addition, another study reported a 4-fold increased prevalence of MetS in PCOS-suffering women, compared to the overall population.50 Previous research has also found a much greater likelihood (4.2- fold) of developing MetS among adolescent Indian girls with PCOS, when compared to those without PCOS.35 In contrast, Hosseinpanah et al did not find a significantly higher frequency of MetS in a sample of Iranian women with PCOS, than that found in healthy subjects.39

Therefore, there is great variation in the prevalence of MetS, even among studies which used the same definition of PCOS. This variability is likely to be due to the following reasons: i) the cut off points used in the different definitions; and ii) inconsistency in the number of elements required by each definition. Consequently, a general and diagnostic definition is required for planning early prevention and for the identification of MetS-susceptible PCOS patients. It is also unclear which definition(s) is/are the best. Some of the previously conducted studies have reported the ATP III to be better than the IDF criteria, in terms of prediction.66,67 In contrast, Tong et al. highlighted the inability of the IDF definition for identifying MetS patients with a high risk of coronary heart disease.68

Previous research has reported that the relationship between PCOS and MetS to be independent of age. In support of previous research, we also found that the heterogeneity in the relationship between PCOS and MetS could not be explained by the participants’ age. Similarly, Vural et al indicated a higher frequency of MetS among women with PCOS in all age groups.62 In contrast, a cross-sectional study reported MetS prevalence of 12.1% for women aged 20-24 years old, 31.7% among 25-29 year olds and 42.9% among those aged 30-34 years old.47 Also, several other studies have found the prevalence of MetS to be heavily age-dependent.69,70 A higher risk of MetS has also been reported among women under 30 years old with PCOS, which highlights the importance of early and regular screening for MetS among young women with PCOS.65

In our study the prevalence of MetS components (e.g. WC, and HTN) were estimated among women with PCOS. This found a high prevalence of WC among these women (52.23%). In previous research, the prevalence of obesity in women with PCOS has been reported to be 30%–75%,71,72 which is extremely high and demonstrates the strong effect of adiposity on the development and maintenance of PCOS.73

The current study also found that the various indicators of MetS, such as high levels of TG and FBS and a low HDL level, were more prevalent among women with PCOS than among the healthy controls. This finding supports previous research which has also found higher rates of MetS components among women with PCOS, than among healthy controls.35,74,75 For instance, research in India found a dyslipidemia rate of 90.2% among adolescent women with PCOS and 21.6% of their sample had high levels of FBS.35 Furthermore, a meta-analysis found higher levels of low-density lipoprotein in women with PCOS, than among healthy controls.74 Several studies have also reported dyslipidemia to be the most frequently identified indicator of metabolic disorder among patients with PCOS, with prevalence rates of up to 70% being reported.5,12,75 The high prevalence of this symptom is thought to be as a result of changes in the concentration of several hormones (insulin, estrogens, and androgens) among women with PCOS, which alters the metabolism of lipoproteins.76 In an effort to remove excess hyperandrogenism and estrogen in women with PCOS, using gonadotrophin‐releasing hormone agonists (GnRHa), research found that after three months of treatment androgen and estrogen levels were reduced and a slight reduction was also found in the levels of triglyceride.77 In contrast, Pirwany et al indicated that metabolic disorder was more closely related to adiposity/insulin metabolism than to circulating androgen levels.78 In general, because of a higher prevalence of dyslipidemia among the PCOS patients, it is important that the levels of serum lipids should be carefully monitored.

This study is a comprehensive systematic review and meta-analysis on the prevalence of MetS, and its components, among women diagnosed with PCOS. An extensive search of 10 databases was made in order to avoid missing any relevant information. However, as with any study this meta-analysis and systematic review had a number of strengths and limitations. The first strength of this study was the comprehensive search strategy which covered 10 databases. In addition, the search and data extraction processes were conducted independently by two authors, reducing the chances that something would be missed. Furthermore, the prevalence of MetS was presented by calculating the ORs using different diagnostic criteria, rather than relying solely on one. Finally, another strength of the study was that the possible sources of heterogeneity across studies were examined using a series of meta-regression analyses.

This study also had a number of limitations, including the fact that non-English studies were not included and that surprisingly there were no studies identified from Africa. Finally, due to sparse data bias, subgroup analysis on the different variables could not be undertaken.

Conclusion

The present study found that women with PCOS had a much higher prevalence of MetS than was found among healthy controls. Therefore, the present study highlights the importance of preventive strategies designed to prevent MetS among women with PCOS. Furthermore, as low HDL and high WC were the most commonly identified components of MetS, among women diagnosed with PCOS, these two components particularly need to be carefully addressed in prevention strategies.

Ethical approval

The present study is based on published data, and hence ethical approval was not required.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This study was funded by the Vice Chancellor for Research and Technology of Maragheh University of Medical Sciences.

Supplementary Materials

Supplementary file 1 contains Figures S1-S5 and Table S1.

Click here for additional data file. (653KB, pdf)

Please cite this article as: Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E, Pakzad R, Sullman MJM, Safiri S. Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and metaanalysis. J Cardiovasc Thorac Res 2018;10(2):56-69. doi: 10.15171/jcvtr.2018.10.

References

  • 1.Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. doi: 10.1186/1741-7015-8-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–8. doi: 10.1210/jc.2005-0628. [DOI] [PubMed] [Google Scholar]
  • 3. Zore T, Joshi NV, Lizneva D, Azziz R. Polycystic Ovarian Syndrome: Long-Term Health Consequences. Semin Reprod Med. Thieme Medical Publishers; 2017. p. 271-81. [DOI] [PubMed]
  • 4.Dokras A, Bochner M, Hollinrake E, Markham S, VanVoorhis B , Jagasia DH . Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106:131–7. doi: 10.1097/01.AOG.0000167408.30893.6b. [DOI] [PubMed] [Google Scholar]
  • 5.Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4797–802. doi: 10.1210/jc.2004-2217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril. 2011;96:1271–4. doi: 10.1016/j.fertnstert.2011.08.006. [DOI] [PubMed] [Google Scholar]
  • 7.Park HR, Choi Y, Lee H-J, Oh J-Y, Hong YS, Sung Y-A. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract. 2007;77:S243–S6. doi: 10.1016/j.diabres.2007.01.065. [DOI] [PubMed] [Google Scholar]
  • 8.Varghese J, Kantharaju S, Thunga S, Joseph N, Singh PK. Prevalence and predictors of metabolic syndrome in women with polycystic ovarian syndrome: a study from Southern India. Int J Reprod Contracept Obstet Gynecol. 2015;4:113–8. doi: 10.5455/2320-1770.ijrcog20150222. [DOI] [Google Scholar]
  • 9.Pasquali R, Gambineri A, Anconetani B. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long‐term oestrogen–progestagen treatment. Clin Endocrinol. 1999;50:517–27. doi: 10.1046/j.1365-2265.1999.00701.x. [DOI] [PubMed] [Google Scholar]
  • 10.Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48–53. doi: 10.1210/jc.2005-1329. [DOI] [PubMed] [Google Scholar]
  • 11.Carmina E, Napoli N, Longo R, Rini G, Lobo R. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5. doi: 10.1530/eje.1.02058. [DOI] [PubMed] [Google Scholar]
  • 12.Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–35. doi: 10.1210/jc.2004-1045. [DOI] [PubMed] [Google Scholar]
  • 13.Ranasinha S, Joham AE, Norman RJ, Shaw JE, Zoungas S, Boyle J. et al. The association between Polycystic Ovary Syndrome (PCOS) and metabolic syndrome: a statistical modelling approach. Clin Endocrinol. 2015;83:879–87. doi: 10.1111/cen.12830. [DOI] [PubMed] [Google Scholar]
  • 14.Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014;12:1. doi: 10.1186/1477-7827-12-89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63. doi: 10.1093/humupd/dmq001. [DOI] [PubMed] [Google Scholar]
  • 16.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google Scholar in evidence reviews and its applicability to grey literature searching. PloS One. 2015;10:e0138237. doi: 10.1371/journal.pone.0138237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. doi: 10.1371/journal.pmed.0040297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S. et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One. 2016;11:e0147601. doi: 10.1371/journal.pone.0147601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kyrkou G, Trakakis E, Chrelias C. Comparison of the prevalence and characteristics of the metabolic syndrome in Greek women with Polycystic Ovary Syndrome in relation with the general population. Hum Reprod. 2015 [Google Scholar]
  • 22.Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol. 2015;52:117–23. doi: 10.1590/S0004-28032015000200008. [DOI] [PubMed] [Google Scholar]
  • 23.Pillai BP, Kumar H, Jayakumar RV, Alur VC, Sheejamol V. The prevalence of metabolic syndrome in polycystic ovary syndrome in a South Indian population and the use of neck circumference in defining metabolic syndrome. Int J Diabetes Dev Ctries. 2015;35:469–75. doi: 10.1590/S0004-28032015000200008. [DOI] [Google Scholar]
  • 24.Madani T, Hosseini R, Ramezanali F, Khalili G, Jahangiri N, Ahmadi J. et al. Metabolic syndrome in infertile women with polycystic ovarian syndrome. Arch Endocrinol Metab. 2016;60(3):199–204. doi: 10.1590/2359-3997000000135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Shabir I, Ganie MA, Zargar MA, Bhat D, Mir MM, Jan A. et al. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian J Endocrinol Metab. 2014;18:364. doi: 10.4103/2230-8210.131186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Figurová J, Dravecká I, Javorský M, Petríková J, Lazúrová I. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities. Wien Klin Wochenschr. 2016;128:641–8. doi: 10.1007/s00508-015-0768-9. [DOI] [PubMed] [Google Scholar]
  • 27.Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014;12:89. doi: 10.1186/1477-7827-12-89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Li R, Yu G, Yang D, Li S, Lu S, Wu X. et al. Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross-sectional study. BMC Endocr Disord. 2014;14:76. doi: 10.1186/1472-6823-14-76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kim MJ, Lim NK, Choi YM, Kim JJ, Hwang KR, Chae SJ. et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea. PloS one. 2014;9:e99252. doi: 10.1371/journal.pone.0099252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Panidis D, Macut D, Tziomalos K. Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol. 2013;78:586–92. doi: 10.1111/cen.12008. [DOI] [PubMed] [Google Scholar]
  • 31.Mandrelle K, Kamath MS, Bondu DJ, Chandy A, Aleyamma T, George K. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. J Hum Reprod Sci. 2012;5:26. doi: 10.4103/0974-1208.97791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Moini A, Javanmard F, Eslami B, Aletaha N. Prevalence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. Iran J Reprod Med. 2012;10:127. [PMC free article] [PubMed] [Google Scholar]
  • 33.Verit FF. The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. Gynecol Endocrinol. 2012;28:365–9. doi: 10.3109/09513590.2011.593931. [DOI] [PubMed] [Google Scholar]
  • 34.Ishak A, Kadir AA, Hussain NHN, Bahari S. Prevalence and Characteristics of Metabolic Syndrome among Polycystic Ovarian Syndrome Patients in Malaysia. Int J Collab Res Intern Med Public Health. 2012;4:1577–88. [Google Scholar]
  • 35.Bhattacharya SM, Jha A. Prevalence and risk of metabolic syndrome in adolescent Indian girls with polycystic ovary syndrome using the 2009 ‘joint interim criteria’. J Obstet Gynaecol Res. 2011;37:1303–7. doi: 10.1111/j.1447-0756.2010.01516.x. [DOI] [PubMed] [Google Scholar]
  • 36.Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci. 2011:16. [PMC free article] [PubMed] [Google Scholar]
  • 37.Vrbíková J, Vondra K, Cibula D, Dvoráková K, Stanická S, Srámková D. et al. Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod. 2005;20:3328–32. doi: 10.1093/humrep/dei221. [DOI] [PubMed] [Google Scholar]
  • 38.Gangale MF, Miele L, Lanzone A, Sagnella F, Martinez D, Tropea A. et al. Long‐term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol. 2011;75:520–7. doi: 10.1111/j.1365-2265.2011.04093.x. [DOI] [PubMed] [Google Scholar]
  • 39.Hosseinpanah F, Barzin M, Tehrani FR, Azizi F. The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study. Clin Endocrinol. 2011;75:692–7. doi: 10.1111/j.1365-2265.2011.04113.x. [DOI] [PubMed] [Google Scholar]
  • 40.Dey R, Mukherjee S, Roybiswas R, Mukhopadhyay A, Biswas S. Association of metabolic syndrome in polycystic ovarian syndrome: an observational study. J Obstet Gynaecol India. 2011;61:176. doi: 10.1007/s13224-011-0020-0. [DOI] [Google Scholar]
  • 41.Bhattacharya SM. Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res. 2008;34:62–6. doi: 10.1111/j.1447-0756.2007.00685.x. [DOI] [PubMed] [Google Scholar]
  • 42.Indhavivadhana S, Wongwananuruk T, Rattanachaiyanont M, Techatraisak K, Leerasiri P, Tanmahasamut P. et al. Prevalence of metabolic syndrome in reproductive-aged polycystic ovary syndrome Thai women. J Med Assoc Thai. 2010;93:653–60. [PubMed] [Google Scholar]
  • 43.Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol. 2009;25:335–43. doi: 10.1080/09513590802630146. [DOI] [PubMed] [Google Scholar]
  • 44.Moradi S, Darvishi N. Evaluation of the Prevalence of Metabolic Syndrome in Women with Polycystic Ovary Syndrome Referred to the Institute of Endocrine and Metabolism. Razi Journal of Medical Sciences. 2009;16(63) [Google Scholar]
  • 45.Ni R-m, Mo Y, Chen X, Zhong J, Liu W, Yang D. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161:411–8. doi: 10.1530/EJE-09-0298. [DOI] [PubMed] [Google Scholar]
  • 46.Gambineri A, Repaci A, Patton L, Grassi I, Pocognoli P, Cognigni GE. et al. Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2009;19:797–804. doi: 10.1016/j.numecd.2009.01.007. [DOI] [PubMed] [Google Scholar]
  • 47.Soares EMM, Azevedo GD, Gadelha RGN, Lemos TMA, Maranhão TMO. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril. 2008;89:649–55. doi: 10.1016/j.fertnstert.2007.03.081. [DOI] [PubMed] [Google Scholar]
  • 48.Attaoua R, Ait El Mkadem S, Radian S, Fica S, Hanzu F, Albu A. et al. FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun. 2008;373:230–4. doi: 10.1016/j.bbrc.2008.06.039. [DOI] [PubMed] [Google Scholar]
  • 49.Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY. et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod. 2008;23:1431–8. doi: 10.1093/humrep/den090. [DOI] [PubMed] [Google Scholar]
  • 50.Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod. 2008;23:2352–8. doi: 10.1093/humrep/den263. [DOI] [PubMed] [Google Scholar]
  • 51.Gulcelik NE, Aral Y, Serter R, Koc G. Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome. J Natl Med Assoc. 2008;100:64–8. doi: 10.1016/s0027-9684(15)31176-7. [DOI] [PubMed] [Google Scholar]
  • 52.Costa L, Viana AdOR , Oliveira Md . Prevalência da síndrome metabólica em portadoras da síndrome dos ovários policísticos. Rev Bras Ginecol Obstet. 2007;29:10–7. doi: 10.1590/S0100-72032007000100003. [DOI] [Google Scholar]
  • 53.Weerakiet S, Bunnag P, Phakdeekitcharoen B. Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria. Gynecol Endocrinol. 2007;23:153–60. doi: 10.1080/09513590701214158. [DOI] [PubMed] [Google Scholar]
  • 54.Marcondes JAM, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol. 2007;51:972–9. doi: 10.1590/S0004-27302007000600012. [DOI] [PubMed] [Google Scholar]
  • 55.Çalışkan E, Kılıç T, Bodur H, Zeteroğlu Ş. The Frequency of Metabolic Syndrome in Women with Polycystic Ovaries at Reproductive Age and Comparison of Different Diagnostic Criteria for Metabolic Syndrome. J Turk Ger Gynecol Assoc. 2007:8. [Google Scholar]
  • 56.Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007;92:4609–14. doi: 10.1210/jc.2007-1343. [DOI] [PubMed] [Google Scholar]
  • 57.Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K. et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2007;115:130–5. doi: 10.1055/s-2007-967093. [DOI] [PubMed] [Google Scholar]
  • 58.Álvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166:2081–6. doi: 10.1001/archinte.166.19.2081. [DOI] [PubMed] [Google Scholar]
  • 59.Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492–7. doi: 10.1210/jc.2005-1666. [DOI] [PubMed] [Google Scholar]
  • 60.Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab. 2006;91:1275–83. doi: 10.1210/jc.2005-1707. [DOI] [PubMed] [Google Scholar]
  • 61.Rabelo-Acevedo M, Ramírez-Vick M. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico. P R Health Sci J. 2005:24. [PubMed] [Google Scholar]
  • 62.Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod. 2005;20:2409–13. doi: 10.1093/humrep/dei100. [DOI] [PubMed] [Google Scholar]
  • 63.Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GG. et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004;27:424–9. doi: 10.1007/BF03345285. [DOI] [PubMed] [Google Scholar]
  • 64.Glueck C, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908–15. doi: 10.1016/S0026-0495(03)00104-5. [DOI] [PubMed] [Google Scholar]
  • 65.Bhattacharya SM. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol. 2010;26:516–20. doi: 10.3109/09513590903367010. [DOI] [PubMed] [Google Scholar]
  • 66.Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P. et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care. 2006;29:901–7. doi: 10.2337/diacare.29.04.06.dc05-2011. [DOI] [PubMed] [Google Scholar]
  • 67.Monami M, Marchionni N, Masotti G, Mannucci E. IDF and ATP‐III definitions of metabolic syndrome in the prediction of all‐cause mortality in type 2 diabetic patients. Diabetes Obes Metab. 2007;9:350–3. doi: 10.1111/j.1463-1326.2006.00615.x. [DOI] [PubMed] [Google Scholar]
  • 68.Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC. et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care. 2007;30:1206–11. doi: 10.2337/dc06-1484. [DOI] [PubMed] [Google Scholar]
  • 69.Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427–36. doi: 10.1001/archinte.163.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Alvarez CA, López FV, Suárez GS, Arias GT, Prieto DM, Díaz GL. [Differences in the prevalence of metabolic syndrome according to the ATP-III and WHO definitions] Med Clin. 2005;124:368–70. doi: 10.1157/13072570. [DOI] [PubMed] [Google Scholar]
  • 71.Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36. doi: 10.1056/NEJMra041536. [DOI] [PubMed] [Google Scholar]
  • 72.Essah P, Nestler J. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006;29:270–80. doi: 10.1007/BF03345554. [DOI] [PubMed] [Google Scholar]
  • 73.Barber T, McCarthy M, Wass J, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65:137–45. doi: 10.1111/j.1365-2265.2006.02587.x. [DOI] [PubMed] [Google Scholar]
  • 74.Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95:1073–9 e11. doi: 10.1016/j.fertnstert.2010.12.027. [DOI] [PubMed] [Google Scholar]
  • 75.Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24:302–12. doi: 10.1210/er.2003-0004. [DOI] [PubMed] [Google Scholar]
  • 76.WILD RA, Painter P, Coulson PB, Carruth KB, Ranney G. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946–51. doi: 10.1210/jcem-61-5-946. [DOI] [PubMed] [Google Scholar]
  • 77.Wild RA, Bartholomew MJ. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome. Am J Obstet Gynecol. 1988;159:423–7. doi: 10.1016/S0002-9378(88)80099-1. [DOI] [PubMed] [Google Scholar]
  • 78.Pirwany I, Fleming R, Greer I, Packard C, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol. 2001;54:447–53. doi: 10.1046/j.1365-2265.2001.01228.x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary file 1 contains Figures S1-S5 and Table S1.

Click here for additional data file. (653KB, pdf)

Articles from Journal of Cardiovascular and Thoracic Research are provided here courtesy of Tabriz University of Medical Sciences

RESOURCES